Qiagen has agreed to an acquisition by private equity firm EQT AB for it to acquire 100% of the company’s shares. The deal is subject to shareholder approval, but both the management and supervisory boards have unanimously recommended acceptance of the all-cash offer price of EUR 46.50 per share.
Qiagen is active in multiple potentially fast-growing end markets like dPCR and bioinformatics and has product launches coming up, supporting strong growth over the long run.
Qiagen will continue to face intense competition in its heavily invested diagnostics markets, which could harm financial returns.
|
Metric
|
QGEN
|
ILMN
|
DHR
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.71 | 54.27 | 33.43 |
Price/Book Value | 3.09 | 14.87 | 3.04 |
Price/Sales | 4.98 | 9.58 | 6.42 |
Price/Cash Flow | 15.52 | 33.18 | 21.56 |
|
Metric
|
QGEN
|
ILMN
|
DHR
|
|---|---|---|---|
Quick Ratio | 2.04 | 1.22 | 1.08 |
Current Ratio | 2.85 | 1.80 | 1.63 |
Interest Coverage | 11.32 | 10.96 | 14.02 |
|
Metric
|
QGEN
|
ILMN
|
DHR
|
|---|---|---|---|
Return on Assets (Normalized) | 8.94% | 6.73% | 5.55% |
Return on Equity (Normalized) | 15.39% | 16.79% | 9.14% |
Return on Invested Capital (Normalized) | 10.05% | 9.37% | 6.75% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|pHmrJ?#R | LOCK|>% | $256B | |||
| Danaher Corp
DHR
| LOCK|k!TS&f$> | LOCK|%&b | $163B | |||
| Agilent Technologies Inc
A
| LOCK|$lF>Xy#& | LOCK|N>@ | $50B | |||
| Waters Corp
WAT
| LOCK|>%M#w> | LOCK|#f | $46B | |||
| IQVIA Holdings Inc
IQV
| LOCK|Xd<WC!B | LOCK|%@<?% | $45B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|$?x^XTkZ | LOCK|Rch | $44B | |||
| Illumina Inc
ILMN
| LOCK|<>>?<# | LOCK|>nk!% | $42B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|#t@$xW>@ | LOCK|SrwqB | $34B | |||
| Labcorp Holdings Inc
LH
| LOCK|#hW>r^b | LOCK|Grbc | $27B | |||
| Quest Diagnostics Inc
DGX
| LOCK|!@pXJx& | LOCK|Dws< | $27B |
United States